Bortezomib in mantle cell lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Investigation

Background:

• Mantle cell lymphoma (MCL) constitutes 6% of non-Hodgkin lymphomas and is a significant focus of clinical research.
• Currently, no definitive curative therapy exists for MCL, highlighting the need for improved treatment strategies.

Purpose of the Study:

• To review the current landscape of Mantle cell lymphoma (MCL) treatment, focusing on front-line therapy intensification and novel therapeutic agents.
• To emphasize the importance of clinical trial participation and the potential role of pharmacogenomics in advancing MCL research.

Main Methods:

• Review of current literature on Mantle cell lymphoma (MCL) treatment protocols.
• Identification of novel therapeutic agents under investigation for MCL.
• Discussion of the role of high-dose therapy, stem cell transplant, and dose-intense chemotherapy regimens.

Main Results:

• Intensified front-line therapy, including high-dose therapy with stem cell transplant or dose-intense chemotherapy, shows benefit in MCL.
• A variety of novel agents, such as proteasome inhibitors (e.g., bortezomib), mTOR inhibitors, Bcl-2 inhibitors, antiangiogenesis agents, and histone deacetylase inhibitors, are under investigation.
• Despite advances, most MCL patients experience relapse, underscoring the need for more effective treatments.

Conclusions:

• There is an ongoing need for effective therapies and curative strategies for Mantle cell lymphoma (MCL).
• Novel agents and intensified treatment approaches represent promising avenues for improving patient outcomes.
• Enrollment in clinical trials, informed by pharmacogenomics and a deeper understanding of MCL biology, is essential for future progress.